HOME >> MEDICINE >> NEWS
Researchers identify brain pathway to explain how Fenfluramine causes weight loss

BOSTON Scientists have identified the molecular pathway in the brain that helps explain how the once-popular diet drug d-Fenfluramine (d-FEN) works to promote weight loss, a discovery reported in the July 26 issue of Science that could provide an opportunity to develop a new anti-obesity treatment without d-FEN's cardiac side effects.

The study, led by a team of researchers at Beth Israel Deaconess Medical Center (BIDMC), also suggests this same brain pathway the melanocortin system is responsible for regulation of body weight at either end of the weight spectrum from obesity at one extreme to anorexia nervosa at the other.

D-FEN, used in combination with phenteramine and known as fen-phen, was banned by the U.S. Food and Drug Administration (FDA) in 1997 after a subset of patients taking the drug developed cardiac complications.

"This study helps close the circle on the role of the melanocortin pathway and adds the serotonin system to the growing list of metabolic signals including leptin that act on the brain's melanocortin neurons, regulating food intake and body weight," explains the study's senior author Joel Elmquist, D.V.M., Ph.D., a neuroscientist and endocrinologist at BIDMC and associate professor of endocrinology and medicine at Harvard Medical School.

The diet drug d-FEN, which is the "fen" part of the fen-phen combination, first came on the market in 1992, and within five years, had been prescribed to millions of individuals who were trying to lose weight. The drug works by increasing the brain's release of serotonin, a "chemical messenger" that, among other things, helps to suppress appetite. Serotonin acts as a neurotransmitter to convey nerve impulses in the brain, and anti-obesity drugs such as fenfluramine, as well as the popular antidepressant medications fluoxetine (Prozac) and sertraline (Zoloft) work by enhancing this effect.

However, as Elmquist explains, d-FEN's popularity was relatively brief:
'"/>

Contact: Bonnie Prescott
bprescot@caregroup.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
25-Jul-2002


Page: 1 2 3

Related medicine news :

1. Researchers search for first sign of congestive heart failure
2. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
3. Researchers close in on breast cancer vaccine
4. Researchers discover link between insulin and Alzheimers
5. Researchers model brains electrical storm during a seizure
6. Researchers track programs success in curbing aggressive behavior
7. Researchers confirm Vioxx nearly doubled cardiovascular risks in cancer prevention study
8. Researchers offer emergency workers a lifeline
9. Researchers discover genetic variant that may explain why women develop M.S. more than men
10. Researchers map the sexual network of an entire high school
11. Researchers hope monkeys can provide new insights into depression

Post Your Comments:
(Date:5/29/2015)... Abington Hospital – Jefferson Health ... hospitals in the nation to join the ... and work toward achieving the Baby-Friendly USA© designation. ... on maternity care practices leading to Baby-Friendly designation. ... Prevention, EMPower is aimed at increasing breastfeeding rates ...
(Date:5/29/2015)... On May 21, 2015, Elle Magazine in article titled ... Botox ?” reported on the four most commonly searched beauty ... to determine these results and then sought expert help to ... example, is how to keep neck skin tight . ... the appropriate age to start receiving Botox injections . ...
(Date:5/29/2015)... The Healthcare Delivery Institute at HORNE ... Training Program (ATP) in Healthcare Delivery Improvement. The ... health care organization ranging from clinicians to CFOs, ... quality improvement in the health care environment. The ... internationally recognized Advanced Training Program at Intermountain Healthcare. ...
(Date:5/29/2015)... 29, 2015 The print component of ... circulation of approximately 250,000 and an estimated readership of ... vast social media strategy, and across a network of ... digital version of the campaign, click here. ... publication. Inside, the actress, model and producer details her ...
(Date:5/29/2015)... Shaila Jiwa, a physiotherapist from Burnaby ... stated in a new announcement that patients of urinary ... commonly seen as a tabooed topic to talk about ... like Shaila Jiwa try to encourage people to come ... is a condition that can be classified under two ...
Breaking Medicine News(10 mins):Health News:Abington Hospital Selected to Join Baby-Friendly Hospital Initiative 2Health News:Botox, Wrinkles and Double Chins: The Most-Asked Beauty Problems According to Google 2Health News:HORNE LLP’s Healthcare Delivery Institute Graduates Class from the Advanced Training Program 2Health News:Patients of Urinary Incontinence Should Not "Hide And Suffer," States Physiotherapist from Burnaby Physiotherapy Clinic 2
(Date:5/29/2015)... 29, 2015  The annual customer satisfaction survey of ... EMR as #1 across all specialties. Every year, ... conducts a poll of EHR users and publishes an ... Praxis EMR topped 348 other systems, ... based criteria used by Black Book. In addition to ...
(Date:5/29/2015)... 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" or ... is delighted to announce its financial results for ... includes revenue for three months of $2,180,276 and ... advanced wound care product sales for the three ... to $1,742,672 compared to $1,400,065 for the same ...
(Date:5/29/2015)... 2015 Amgen (NASDAQ: AMGN ) ... 3, global, randomized, placebo-controlled trials evaluating AMG 416, ... hyperparathyroidism (SHPT) in patients with chronic kidney disease ... endpoint, demonstrating that a greater proportion of patients ... than 30 percent reduction in parathyroid hormone (PTH) ...
Breaking Medicine Technology:Praxis EMR Ranks #1 for Physician Satisfaction in Black Book's 2015 Survey of Solo and Small Practices 2Covalon Announces Strong Second Quarter Results 2Covalon Announces Strong Second Quarter Results 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7
Cached News: